President Donald Trump’s executive order regarding childhood vaccinations sparked backlash from public health experts. This directive seeks to separate combination vaccines, such as the measles, mumps, and rubella (MMR) vaccine, into individual shots, and space out other vaccinations.
Challenges and Implications
The implementation of this order presents substantial financial and logistical hurdles for parents, healthcare providers, and pharmaceutical companies. Drugmakers would need to revive production of individual vaccines not commonly used in the U.S. for decades. Additionally, new manufacturing plants would be necessary, increasing the nation’s vaccine supply needs.
Parents would face added inconvenience and cost, having to visit healthcare providers more frequently for individual vaccinations. Pediatricians could experience increased demands on their resources, including syringes and medical supplies. This change could sharply increase healthcare expenses and complicate immunization schedules.
Concerns from Health Experts
Research indicates combination vaccines are effective in ensuring children receive full protection from infectious diseases before entering school. Experts assert no scientific justification supports Trump’s plan. Dr. Anna Durbin, a public health expert at Johns Hopkins Bloomberg School, described the proposal as poor public health policy.
The executive order instructs federal officials to develop plans for disaggregating the MMR shot and adjusting vaccination schedules within 90 days. However, former FDA vaccine chief Dr. Jesse Goodman argues these adjustments would require extensive research and substantial investment in new manufacturing facilities.
Impacts on Vaccine Manufacturers
There are no standalone vaccines for measles, mumps, or rubella currently available in the U.S. Combination vaccines have been the standard since the 1970s. Pharmaceutical companies may need to conduct extensive studies to demonstrate new individual vaccines’ efficacy and safety.
Merck and GSK, major vaccine producers, expressed confidence in their combination shots’ safety and effectiveness. They also noted there is no scientific evidence supporting the separation of MMR components into individual shots.
Practical Concerns for Parents
Currently, the MMR vaccine is administered in two doses at ages 1 and 4. Separating it into individual components would increase appointments to six. Moreover, spacing out other vaccines would further increase visits, potentially discouraging timely immunization.
Dr. Durbin noted such changes could lead to fewer children being vaccinated due to the inconvenience and increased costs. Despite Trump’s longstanding views on reducing vaccine doses, breaking up combination shots might result in children receiving more shots than other nations.
Legal and Market Realities
Despite the executive order’s directives, neither the White House nor the FDA can compel drugmakers to produce new vaccines, especially when they may compete with existing products.
The order also suggests states consider updating their laws. However, experts doubt significant changes will result from the directive. Institutions like state governments hold the authority to mandate vaccinations for schoolchildren.